Patent · US Active

Alpha-synuclein kinase

US7553639B2 · kind B2 · utility

1Cited by

1References

7Claims

0Family size

Assignee

Elan Pharma International Ltd. · IE

Inventors

Tami J. Chilcote · San Francisco, US
Kelly Banducci · Pleasanton, US
Normand Frigon · Pleasant Hill, US
Guriqbal Basi · Palo Alto, US
John P. Anderson · Langenfeld, DE
Jason Goldstein · Burlingame, US
Irene Griswold-Prenner · Jackson, US
David Chereau · San Mateo, US

Key dates

Filing date	Jan 30, 2007
Grant date	Jun 30, 2009
Priority date	—
Expiry date	Mar 27, 2027

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/28
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 and GRK6 kinases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.